CN1289671C - 对人肿瘤坏死因子α具有特异性的抗体分子及其用途 - Google Patents

对人肿瘤坏死因子α具有特异性的抗体分子及其用途 Download PDF

Info

Publication number
CN1289671C
CN1289671C CNB018016294A CN01801629A CN1289671C CN 1289671 C CN1289671 C CN 1289671C CN B018016294 A CNB018016294 A CN B018016294A CN 01801629 A CN01801629 A CN 01801629A CN 1289671 C CN1289671 C CN 1289671C
Authority
CN
China
Prior art keywords
seq
antibody molecule
heavy chain
sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018016294A
Other languages
English (en)
Chinese (zh)
Other versions
CN1383450A (zh
Inventor
D·S·阿斯瓦尔
D·T·布劳恩
A·N·C·维尔
A·G·波普莱维尔
A·P·查普曼
D·J·金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1289671(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of CN1383450A publication Critical patent/CN1383450A/zh
Application granted granted Critical
Publication of CN1289671C publication Critical patent/CN1289671C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
CNB018016294A 2000-06-06 2001-06-05 对人肿瘤坏死因子α具有特异性的抗体分子及其用途 Expired - Lifetime CN1289671C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0013810.7 2000-06-06
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products

Publications (2)

Publication Number Publication Date
CN1383450A CN1383450A (zh) 2002-12-04
CN1289671C true CN1289671C (zh) 2006-12-13

Family

ID=9893121

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018016294A Expired - Lifetime CN1289671C (zh) 2000-06-06 2001-06-05 对人肿瘤坏死因子α具有特异性的抗体分子及其用途

Country Status (42)

Country Link
US (4) US7012135B2 (2)
EP (4) EP1287140B1 (2)
JP (3) JP4064812B2 (2)
KR (1) KR20020047097A (2)
CN (1) CN1289671C (2)
AP (1) AP2092A (2)
AR (1) AR033978A1 (2)
AT (1) ATE451460T1 (2)
AU (1) AU783756B2 (2)
BE (1) BE2010C019I2 (2)
BG (1) BG66072B1 (2)
BR (2) BRPI0106682B8 (2)
CA (2) CA2380298C (2)
CY (6) CY1109889T1 (2)
CZ (1) CZ300737B6 (2)
DE (3) DE122010000027I1 (2)
DK (4) DK2230308T3 (2)
EC (1) ECSP024210A (2)
ES (5) ES2707714T3 (2)
FR (1) FR10C0015I2 (2)
GB (2) GB0013810D0 (2)
HU (4) HU230561B1 (2)
IL (3) IL147992A0 (2)
IS (2) IS2808B (2)
LT (1) LT2308975T (2)
LU (1) LU91674I2 (2)
MX (1) MXPA01013440A (2)
MY (1) MY136603A (2)
NL (1) NL300982I9 (2)
NO (4) NO334808B1 (2)
NZ (1) NZ516596A (2)
OA (1) OA12282A (2)
PE (1) PE20020292A1 (2)
PL (2) PL212738B1 (2)
PT (4) PT3059314T (2)
RU (1) RU2303604C2 (2)
SI (3) SI1287140T1 (2)
SK (1) SK288343B6 (2)
TR (1) TR201900227T4 (2)
TW (2) TWI316088B (2)
WO (1) WO2001094585A1 (2)
ZA (1) ZA200200097B (2)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
ES2358505T3 (es) * 2002-03-20 2011-05-11 Ucb Pharma, S.A. Métodos para analizar isómeros de disulfuro de anticuerpos.
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SI2371392T1 (sl) * 2002-05-02 2015-10-30 Wyeth Holdings Llc Konjugati derivat-nosilec kaliheamicina
ATE518885T1 (de) * 2002-05-28 2011-08-15 Ucb Pharma Sa Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2311867A1 (en) 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1597299A2 (en) * 2003-02-19 2005-11-23 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
CN1845938B (zh) * 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
JP5544063B2 (ja) * 2003-08-13 2014-07-09 サンド・アクチエンゲゼルシヤフト 組換えポリペプチドの生産のための発現ベクター、形質転換宿主細胞及び発酵方法
ES2391457T3 (es) * 2003-08-13 2012-11-26 Sandoz Ag Procedimiento para la purificación de polipéptidos recombinantes
GB0319601D0 (en) 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US8022040B2 (en) * 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
ES2359567T3 (es) * 2004-12-29 2011-05-24 Yuhan Corporation Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa.
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
NZ563213A (en) * 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
NZ563580A (en) 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
JP2009533347A (ja) * 2006-04-07 2009-09-17 ネクター セラピューティックス エイエル，コーポレイション 抗ＴＮＦα抗体の複合体
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
EP2007426A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
WO2008005429A2 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2678367C (en) * 2007-03-02 2014-07-08 Farnam Companies, Inc. Sustained release compositions using wax-like materials
JP2010532749A (ja) * 2007-06-07 2010-10-14 サーモディクス ファーマシューティカルズ， インコーポレイテッド 質量を削減した長時間作用剤形
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
RU2010136988A (ru) * 2008-02-05 2012-03-20 Деленекс Терапьютикс Аг (Ch) Антигенсвязывающие полипептиды против дегенерации хряща
MX2010012052A (es) * 2008-05-07 2010-12-14 Novo Nordisk As Anticuerpos humanizados contra interferon-alfa humano.
PL3628686T3 (pl) 2008-06-25 2022-02-28 Novartis Ag Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
CN104004094B (zh) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
MX345039B (es) * 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
EP2480661A1 (en) 2009-09-24 2012-08-01 UCB Pharma, S.A. Bacterial host strain
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
BR112012022342A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
WO2011127141A1 (en) 2010-04-07 2011-10-13 Abbott Laboratories TNF-α BINDING PROTEINS
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
WO2012164083A1 (en) 2011-06-01 2012-12-06 Actogenix N.V. Polycistronic expression system for bacteria
HRP20180226T1 (hr) 2011-07-13 2018-03-09 Ucb Biopharma Sprl Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
WO2013041672A1 (en) 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
EP3382006B1 (en) 2011-09-23 2021-02-17 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
CN104520328B (zh) 2012-08-13 2019-06-07 霍夫曼-拉罗奇有限公司 抗锯齿蛋白抗体及使用方法
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
KR102537099B1 (ko) 2014-12-22 2023-05-25 유씨비 바이오파마 에스알엘 단백질 제조 방법
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
CA3011331C (en) 2016-01-14 2025-05-13 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
MY194619A (en) * 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018374634A1 (en) 2017-12-01 2020-05-28 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
EP4291227A2 (en) 2021-02-15 2023-12-20 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
EP4393937A4 (en) 2021-08-26 2025-12-31 Duality Biologics Shanghai Co Ltd STEROID COMPOUND AND CONJUGATE OF THIS ONE
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
MX2024003696A (es) 2021-09-24 2024-05-29 Xbrane Biopharma Ab Construcciones de adn y celulas huespedes para expresar proteinas recombinantes.
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
AU6852594A (en) * 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU9262598A (en) * 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
GB0128386D0 (en) 2002-01-16
RU2303604C2 (ru) 2007-07-27
BR0106682A (pt) 2002-05-14
DE122010000027I1 (de) 2010-08-12
IL147992A0 (en) 2002-09-12
IS6217A (is) 2002-01-03
BG66072B1 (bg) 2011-01-31
TWI316088B (en) 2009-10-21
DE10192353T1 (de) 2003-05-22
PL399351A1 (pl) 2012-12-17
NO20020554D0 (no) 2002-02-04
US20060233800A1 (en) 2006-10-19
HU230561B1 (hu) 2016-12-28
ZA200200097B (en) 2003-01-06
CY2019018I1 (el) 2020-05-29
CA2707766A1 (en) 2001-12-13
CY1109889T1 (el) 2012-01-25
BE2010C019I2 (2) 2020-08-20
CN1383450A (zh) 2002-12-04
FR10C0015I1 (2) 2010-04-16
HU230669B1 (hu) 2017-07-28
CZ2002837A3 (cs) 2002-05-15
NO2014026I1 (no) 2014-10-23
MY136603A (en) 2008-10-31
US20030026805A1 (en) 2003-02-06
GB2366800B (en) 2005-01-19
BRPI0106682B1 (pt) 2020-10-13
IS3016B (is) 2019-10-15
SI2308975T1 (sl) 2016-11-30
JP2007105043A (ja) 2007-04-26
PT2308975T (pt) 2016-11-14
US7402662B2 (en) 2008-07-22
NO20020554L (no) 2002-04-08
DK2308975T3 (da) 2016-10-31
BRPI0106682B8 (pt) 2021-05-25
ECSP024210A (es) 2002-05-23
NL300982I9 (nl) 2019-05-06
KR20020047097A (ko) 2002-06-21
SI2230308T1 (sl) 2013-06-28
ES2230975A1 (es) 2005-05-01
AU783756B2 (en) 2005-12-01
NO2014026I2 (no) 2018-02-14
CY1118220T1 (el) 2017-06-28
GB2366800A (en) 2002-03-20
LU91674I2 (fr) 2010-05-31
CA2380298C (en) 2010-09-28
US20020151682A1 (en) 2002-10-17
JP5185143B2 (ja) 2013-04-17
ES2403217T3 (es) 2013-05-16
AU6051101A (en) 2001-12-17
TW200817430A (en) 2008-04-16
HUS1700013I1 (hu) 2017-08-28
HK1051385A1 (en) 2003-08-01
MXPA01013440A (es) 2003-09-04
IS2808B (is) 2012-09-15
US7977464B2 (en) 2011-07-12
AR033978A1 (es) 2004-01-21
PE20020292A1 (es) 2002-05-08
CZ300737B6 (cs) 2009-07-29
PT1287140E (pt) 2010-03-08
BG106278A (bg) 2002-12-29
HUP1600016A2 (en) 2002-10-28
NO20160694A1 (no) 2002-04-08
EP2230308A1 (en) 2010-09-22
LU91674I9 (2) 2019-01-03
SK3152002A3 (en) 2002-07-02
NO334808B1 (no) 2014-06-02
NZ516596A (en) 2004-07-30
CY1114143T1 (el) 2016-07-27
GB0013810D0 (en) 2000-07-26
JP4476989B2 (ja) 2010-06-09
NO20131316L (no) 2002-04-08
ES2230975B2 (es) 2007-04-16
ATE451460T1 (de) 2009-12-15
CY2010011I2 (el) 2012-01-25
PL353960A1 (en) 2003-12-15
JP4064812B2 (ja) 2008-03-19
EP2308975B1 (en) 2016-08-10
NO341218B1 (no) 2017-09-11
CY2019018I2 (el) 2020-05-29
US7186820B2 (en) 2007-03-06
ES2600080T3 (es) 2017-02-07
SI1287140T1 (sl) 2010-04-30
EP2230308B1 (en) 2013-01-23
IL147992A (en) 2009-06-15
HU230553B1 (hu) 2016-11-28
HK1148776A1 (en) 2011-09-16
DK3059314T3 (en) 2019-02-18
HUP0202346A2 (en) 2002-10-28
AP2092A (en) 2010-02-28
NL300982I1 (2) 2019-05-01
ES2337763T3 (es) 2010-04-29
SK288343B6 (sk) 2016-04-01
PL212738B1 (pl) 2012-11-30
EP2308975A1 (en) 2011-04-13
US20080269465A1 (en) 2008-10-30
EP3059314B1 (en) 2018-10-24
LT2308975T (lt) 2016-11-10
PT2230308E (pt) 2013-05-03
CY1121173T1 (el) 2020-05-29
EP3059314A1 (en) 2016-08-24
NO339282B1 (no) 2016-11-21
PL218516B1 (pl) 2014-12-31
AP2002002690A0 (en) 2002-12-31
US7012135B2 (en) 2006-03-14
EP1287140A1 (en) 2003-03-05
JP2009171966A (ja) 2009-08-06
DK1287140T3 (da) 2010-04-19
EP1287140B1 (en) 2009-12-09
HUP1600483A2 (2) 2002-10-28
DK2230308T3 (da) 2013-05-06
FR10C0015I2 (fr) 2011-12-30
OA12282A (en) 2006-05-11
IL195085A0 (en) 2009-08-03
WO2001094585A1 (en) 2001-12-13
PT3059314T (pt) 2019-02-01
CA2707766C (en) 2013-05-21
CY2010011I1 (el) 2012-01-25
TWI353358B (en) 2011-12-01
ES2707714T3 (es) 2019-04-04
HUP0202346A3 (en) 2004-11-29
TR201900227T4 (tr) 2019-02-21
CA2380298A1 (en) 2001-12-13
JP2003535591A (ja) 2003-12-02
DE60140738D1 (de) 2010-01-21

Similar Documents

Publication Publication Date Title
CN1289671C (zh) 对人肿瘤坏死因子α具有特异性的抗体分子及其用途
CN1745103A (zh) 对人IL－1β具有特异性的抗体分子
CN1211123C (zh) 抗白细胞粘附分子vla－4的人源化抗体
CN1105728C (zh) 用于治疗il4介导疾病的重组il4抗体
CN1271205C (zh) 重新构建的人抗hm1.24抗体
CN1662558A (zh) 人cd22特异性抗体及其治疗和诊断应用
CN1795009A (zh) 抗－cd33抗体和使用其治疗急性髓性白血病的方法
CN1076966A (zh) 抗人白细胞介素-4的人性化单克隆抗体的克隆和表达
CN1308676A (zh) 抗cd23抗体、抗cd23抗体衍生物及其治疗性应用
CN1678634A (zh) 免疫球蛋白单个变体抗原结合区及其特异性构建体
CN1845938A (zh) 多肽
CN1638796A (zh) 施用抗TNFα抗体的方法
CN1297480A (zh) 抗体片段－聚合物偶联物和人源化的抗白细胞介素－8单克隆抗体
CN1688338A (zh) 对免疫系统分子进行人源化的方法
CN1753911A (zh) 调节血管生成的α5β1整合素的嵌合的和人源化的抗体
CN1656122A (zh) 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
CN1200737A (zh) 用于人治疗的重组抗cd4抗体
CN1599624A (zh) 抑制血液凝固的抗体及其使用方法
CN1958615A (zh) 功能人源化抗人cd20抗体及其应用
CN1606569A (zh) 具有mn结合和细胞粘附中和活性的人类抗体
CN1531554A (zh) 血纤维蛋白d-二聚体片段特异性的、来源于dd-3b6/22的人源化抗体
CN1156460A (zh) 抗人白细胞介素-8的重构人抗体
CN1230446C (zh) 识别抗原ior c2的抗体和fv片段
CN1073158C (zh) 抗表皮生长因子受体的单链可变区片段和抗体
CN1717251A (zh) 用于治疗动脉粥样硬化的肽基被动免疫接种疗法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: UCB PHARMACY CO.,LTD.

Free format text: FORMER OWNER: CELLTECH R. + D. LTD.

Effective date: 20091218

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20091218

Address after: Brussels

Patentee after: UCB Pharma S.A.

Address before: Burke County, England

Patentee before: Celletech Chiroscience Ltd

CX01 Expiry of patent term

Granted publication date: 20061213

CX01 Expiry of patent term